GLP-1s work by mimicking the GLP-1 incretin hormone your body already makes that lowers blood sugar and controls appetite
Tirzepatide is a GIP and GLP-1 receptor antagonist that should be approved for weight loss this year by the FDA
Published phase 2 research reported that the most common adverse events in retatrutide groups were gastrointestinal, dose-related, and mostly mild to moderate in severity
Wang W, Castro LA, Hoyos M, Mallouk TE
In another child who accidentally ingested 400 mg/kg VPA, decreased -oxidation and markedly increased -oxidation were also observed, and the concentration of 4-en-VPA was markedly increased, although there was neither hyperammonaemia nor signs of liver dysfunction [70]
9 Materials and methods A structured literature review (PRISMA 2020) was conducted across PubMed, Embase, Cochrane Library, Scopus, and Google Scholar to 31 January 2026